Drug‐induced vitiligo: a case/non‐case study in Vigibase®, the WHO pharmacovigilance database. (27th April 2020)

• Record Type: Journal Article
• Authors: Anthony, Norah; Bourneau‐martin, Delphine; Ghamrawi, Sarah; Lagarce, Laurence; Babin, Marina; Briet, Marie
• Is Part Of: Fundamental & clinical pharmacology. Volume 34:Number 6(2020)
• Page Start: 736
• Page End: 742
• Publication Date: 2020-04-27
• Subjects: antibodies monoclonal -- interferons -- pharmacovigilance -- Vitiligo; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/fcp.12558
• Languages: English
• ISSNs: 0767-3981

Abstract

Abstract: Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase ®, the WHO pharmacovigilance database. A case/non‐case study was carried out by defining cases as vitiligo reports and non‐cases as all other reports. The reporting odds ratio (ROR) was calculated for the 'suspected' drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49 ± 20 years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5, 5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF‐alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF‐alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors.